학술논문
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With METExon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
Document Type
Article
Author
Lau, Sally C.M.; Perdrizet, Kirstin; Fung, Andrea S.; Mata, Danilo Giffoni M.M.; Weiss, Jessica; Holzapfel, Nick; Liu, Geoffrey; Bradbury, Penelope A.; Shepherd, Frances A.; Sacher, Adrian G.; Feilotter, Harriet; Sheffield, Brandon; Hwang, David; Tsao, Ming Sound; Cheng, Susanna; Cheema, Parneet; Leighl, Natasha B.
Source
JTO Clinical and Research Reports; October 2023, Vol. 4 Issue: 10
Subject
Language
ISSN
26663643
Abstract
NSCLC with METexon 14 skipping mutation (METex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore, sought to characterize the treatment patterns, outcomes, and emerging issues of treatment sequencing in patients with METex14-mutant NSCLC.